Abstract:In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is 'fully human', T cell epitopes that are contained in the sequences of the biologic may activate the immune system, enabling the development of anti-drug antibodies that can reduce drug efficacy and may contribute to adverse events. Computational tools that identify T cell epitopes from primary amino acid sequences have been used to assess the immunogenic potential of therapeutic candidates for several decades. To facilitate larger scale analyses and accelerate preclinical immunogenicity risk assessment, our group developed an integrated web-based platform called ISPRI, (Immunogenicity Screening and Protein Re-engineering Interface) that provides hands-on access through a secure web-based interface for scientists working in large and mid-sized biotech companies in the US, Europe, and Japan. This toolkit has evolved and now contains an array of algorithms that can be used individually and/or consecutively for immunogenicity assessment and protein engineering. Most analyses start with the advanced epitope mapping tool (EpiMatrix), then proceed to identify epitope clusters using ClustiMer, and then use a tool called JanusMatrix to define whether any of the T cell epitope clusters may generate a regulatory T cell response which may diminish or eliminate anti-drug antibody formation. Candidates can be compared to similar products on a normalized immunogenicity scale. Should modifications to the biologic sequence be an option, a tool for moderating putative immunogenicity by editing T cell epitopes out of the sequence is available (OptiMatrix). Although this perspective discusses the in-silico immunogenicity risk assessment for monoclonal antibodies, bi-specifics, multi-specifics, and antibody-drug conjugates, the analysis of additional therapeutic modalities such as enzyme replacement proteins, blood factor proteins, CAR-T, gene therapy products, and peptide drugs is also made available on the ISPRI platform. ISPRI (Interactive Screening and Protein Reengineering Interface) : Integrated, cloud-based, comprehensive toolkit for Immunogenicity Risk Assessment. EpiMatrix Immunogenicity Score : Combined T effector and Treg Epitope Content per unit protein. Tregitopes : Treg Epitopes found in IgG Framework that have been shown to modulate antigen-specific effector T cell responses. ClustiMer : Tool for identifying epitope rich polypeptides from within a given protein sequence. JanusMatrix : Tool for Predicting Tolerance, Putative Treg Epitopes, and Anti-self-immune responses. OptiMatrix : Tool for modifying T cell epitope sequences to reduce (or enhance) MHC binding.

What problem does this paper attempt to address?

### What problems does this paper attempt to solve? This paper mainly explores how to evaluate the **immunogenicity risk** of therapeutic antibodies through **in silico methods** and screen the potential impact of their homology with humans. Specifically, the research aims to: 1. **Identify potential T - cell epitopes**: Use computational tools to identify T - cell epitopes from the primary amino acid sequence of proteins that may trigger an immune response. These epitopes may activate T - cells, leading to the production of anti - drug antibodies (ADA), thereby reducing drug efficacy and potentially causing adverse events. 2. **Evaluate immunogenicity risk**: Develop and apply a series of computational tools to evaluate the immunogenicity risk of therapeutic antibodies. These tools can not only predict potential T - cell epitopes but also assess whether these epitopes may trigger regulatory T - cell (Treg cell) responses, thereby reducing or eliminating the formation of anti - drug antibodies. 3. **Optimize protein engineering**: Provide tools and techniques to reduce (or enhance) MHC binding by editing T - cell epitopes, thereby reducing the immunogenicity risk of biological agents. This includes modifying the sequence of biological agents to remove potential immunogenic epitopes. 4. **Large - scale analysis and accelerate pre - clinical evaluation**: Develop an integrated Web platform, ISPRI (Immunogenicity Screening and Protein Re - engineering Interface), for large - scale analysis and accelerating pre - clinical immunogenicity risk assessment of therapeutic antibodies. This platform provides scientists with the ability to access and operate these tools through a secure Web interface. ### Key technologies and tools - **EpiMatrix**: An epitope prediction tool based on the position - specific scoring matrix (PSSM), used to evaluate the binding potential of 9 - mer fragments in the input sequence with common HLA - DR supertype alleles. - **ClustiMer**: An algorithm for identifying high - density T - cell epitope clusters, which may be key areas for immune responses. - **JanusMatrix**: Used to evaluate the homology between T - cell epitopes and the human proteome and identify epitopes that may trigger tolerance responses. - **OptiMatrix**: Used to optimize protein sequences by editing T - cell epitopes to reduce their immunogenicity. ### Application scope These tools can be applied not only to monoclonal antibodies (mAbs) but also extended to the immunogenicity risk assessment of other treatment modalities such as bispecific antibodies, multispecific antibodies, antibody - drug conjugates (ADCs), enzyme - replacement proteins, blood - factor proteins, CAR - T cell therapies, gene - therapy products, and peptide drugs. Through these methods, researchers hope to identify and reduce the immunogenicity risk of therapeutic biological agents earlier, thereby improving the safety and effectiveness of drugs.

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

Predicting Immunogenicity Risk in Biopharmaceuticals

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

Explainable Machine Learning for Profiling the Immunological Synapse and Functional Characterization of Therapeutic Antibodies.

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics

In Silico Immunogenicity Assessment of Therapeutic Peptides

In Silico Approaches to Deliver Better Antibodies by Design: The Past, the Present and the Future

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

Abstract 4115: Unleashing the power of MHC associated peptide proteomics: Immunogenicity assessment of oncology drugs

In silico high throughput mutagenesis and screening of signal peptides to mitigate N-terminal heterogeneity of recombinant monoclonal antibodies

AI driven B-cell Immunotherapy Design

A Peptide Microarray Platform Approach for Discovery of Immunodominant Antibody Epitopes

Five computational developability guidelines for therapeutic antibody profiling

Multi-epitope vaccines, from design to expression; an in silico approach

Immunogenicity Risk Assessment of Process-related Impurities in an Engineered T cell Receptor Cellular Product

Assessment of cancer and virus antigens for cross-reactivity in human tissues

Prediction of immunogenicity for humanized and full human therapeutic antibodies

Abstract 2944: A high-throughput screening system for identifying therapeutic targets in immuno-oncology

BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning

A Computer Screening Approach to Immunoglobulin Superfamily Structures and Interactions: Discovery of Small Non-Peptidic CD4 Inhibitors As Novel Immunotherapeutics.